Semi-Annual Statement Of Cash Flows

Immuno-Biological Laboratories Co., Ltd. - Filing #7325711

Concept 2023-04-01 to
2024-03-31
As at
2024-03-31
2023-04-01 to
2024-03-31
As at
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
As at
2022-03-31
Semi-annual statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
124,644,000 JPY
124,225,000 JPY
-622,162,000 JPY
-280,611,000 JPY
Depreciation
2,333,000 JPY
JPY
Impairment losses
602,000 JPY
804,000 JPY
Increase (decrease) in allowance for doubtful accounts
-6,697,000 JPY
6,697,000 JPY
Interest and dividend income
-93,000 JPY
-1,356,000 JPY
Interest expenses
1,130,000 JPY
1,073,000 JPY
Foreign exchange losses (gains)
-2,700,000 JPY
-2,084,000 JPY
Decrease (increase) in trade receivables
32,707,000 JPY
-49,145,000 JPY
Decrease (increase) in inventories
-3,898,000 JPY
-6,320,000 JPY
Increase (decrease) in trade payables
-1,352,000 JPY
1,767,000 JPY
Other, net
-8,952,000 JPY
21,161,000 JPY
Subtotal
144,191,000 JPY
35,588,000 JPY
Interest and dividends received
2,818,000 JPY
288,000 JPY
Interest paid
-3,931,000 JPY
-1,041,000 JPY
Income taxes paid
-9,302,000 JPY
-8,376,000 JPY
Net cash provided by (used in) operating activities
133,775,000 JPY
26,458,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-16,160,000 JPY
JPY
Other, net
164,000 JPY
1,250,000 JPY
Net cash provided by (used in) investing activities
-24,496,000 JPY
30,036,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
10,000,000 JPY
JPY
Repayments of long-term borrowings
-14,008,000 JPY
-4,008,000 JPY
Net cash provided by (used in) financing activities
991,000 JPY
991,000 JPY
Other, net
0 JPY
0 JPY
Effect of exchange rate change on cash and cash equivalents
2,700,000 JPY
2,084,000 JPY
Net increase (decrease) in cash and cash equivalents
112,971,000 JPY
59,571,000 JPY
Cash and cash equivalents
674,969,000 JPY
561,997,000 JPY
449,184,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.